Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BTK C481S |
| Therapy | Ibrutinib |
| Indication/Tumor Type | mantle cell lymphoma |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BTK C481S | mantle cell lymphoma | resistant | Ibrutinib | Case Reports/Case Series | Actionable | In a clinical study, BTK C481S was identified as an acquired mutation that confers resistance to Imbruvica (ibrutinib) in two patients with mantle cell lymphoma who relapsed after a durable response (PMID: 25082755). | 25082755 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (25082755) | Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. | Full reference... |